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1. ABSTRACT 
 
The mechanisms that permit adult tissues to 
regenerate are the object of intense study. Liver 
regeneration is a research area of considerable 
interest both from pathological and from 
physiological perspectives. One of the best models of 
the regenerative process is the two-thirds partial 
hepatectomy (PH). After PH, the remnant liver starts 
a series of timed responses that first favor cell growth 
and then halts hepatocyte proliferation once liver 
function is fully restored. The mechanisms regulating 
this process are complex and involve many cellular 
events. Initiation of liver regeneration requires the 
injury-related cytokines tumor necrosis factor-α 
(TNF-α) and interleukin 6 (IL-6), and involves the 
activation of cytokine-regulated transcription factors 
such as NF-κB and STAT3. An important event that 
takes place in the hours immediately after PH is the 
induction of nitric oxide synthase 2 (NOS-2) and 
cyclooxygenase 2 (COX-2), and the consequent 
release of nitric oxide (NO) and prostaglandins 
(PGs). NO is involved in the vascular readaptation 
after PH, favoring a general permeability to growth 
factors throughout the organ . This review examines 
the mechanisms that regulate NO release during liver 
regeneration and the animal models used to identify 
these pathways. 
 
2. INTRODUCTION 
 
Liver regeneration is a complex,
evolutionarily conserved process directed at restoring
liver mass after liver injury by toxic and xenobiotic
compounds or after surgical resection. In humans,
liver regeneration occurs most frequently after liver
damage by ischaemia or hepatitis. This regenerative
capacity of the liver has provided new treatment
options for patients with liver damage, and in recent
years the use of partial livers from living donors has
greatly increased. In this context, understanding the 
molecular bases of liver regeneration might enable us 
to explain aspects of clinical liver disease that require 
liver regeneration, and could lead to the development 
of new pharmacological therapies and surgical 
approaches.  
 
3. PARTIAL HEPATECTOMY AS A MODEL 
OF LIVER REGENERATION 
 
The rodent PH model has been used 
extensively for the study of liver regeneration (1). In 
this model, two thirds of the liver are surgically 
removed, and the remaining liver initiates a series of 
timed responses that first favor cell growth and 
inhibit apoptosis, and later halt hepatocyte 
proliferation once the original liver mass and liver 
function are restored (2-5). Under these conditions, 
liver regeneration is accomplished by proliferation of 
all existing mature cell populations resident in the 
remaining organ. These populations include 
hepatocytes, biliary epithelial cells, fenestrated 
endothelial cells and Kupffer and Ito cells. 
Nonetheless, hepatocytes are the first cells to 
proliferate (6), which suggests that these cells 
provide the mitogenic stimuli for proliferation of the 
other cell types (7-9).  
 
Rapid changes in gene expression and the 
activation of receptors and transcription factors occur 
immediately after PH (6,10). Indeed, it is estimated 
that ∼70 genes increase their expression in the period 
immediately after PH (11). The signaling pathways 
underlying the early priming phase of liver 
regeneration are thought to be triggered by the 
synergistic effect of a wide array of stimuli released 
into the portal circulation, including cytokines (12),
prostaglandins (13), hormones (6), reactive oxygen 
species (14), and lipopolysaccharides (15). This 
complex network acts in an orderly manner, 
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involving cytokines (TNF-α and IL-6) and growth
factors (hepatocyte growth factor (HGF), epidermal
growth factor (EGF), transforming growth factors
(TGFs), insulin and glucagons, as well as their
downstream transcription factors STAT3 and nuclear
factor NF–κB (figure 1). 
 
 
3.1. Use of modified mouse models in liver 
regeneration studies. 
The sequence of events triggering liver 
regeneration after acute loss of hepatic mass has been 
extensively studied in modified mouse models: 
transgenic mice that overexpress specific genes and 
knockout animals with functional inactivation or gene 
deletion. These models have contributed to a better 
knowledge of the mechanisms that initiate liver 
regeneration and the genes and proteins that are 
rapidly activated in the remnant liver after partial 
hepatectomy.  However, these models do not always 
provide accurate information about the crucial role of 
genes because signaling pathways involved in liver 
regeneration are coordinated and redundant; and in 
general, deletion or inactivation of a gene delays but 
does not impair regeneration. Indeed, few models 
have been described in which liver regeneration after 
PH is impaired to the extent to promote animal death. 
 
3.1.1. Cytokine-dependent pathways 
Cytokines play a prominent role in the 
initiation of liver regeneration. A rapid release of 
TNF-α (16) and IL-6 (17) has been observed after 
PH, leading to the activation of cytokine-regulated 
transcription factors such as NF-κB (18) and STAT-3 
(19) in the liver remnant. Studies by Yamada et al. 
with knockout mice lacking either TNF receptor 1 
(TNFR-1) or receptor 2 (TNFR-2) demonstrated that 
TNFR-1, but not TNFR-2, is necessary for liver 
regeneration (20-22). Indeed, mice lacking TNFR-1 
show defects in DNA synthesis after PH, and 
decreases in IL-6 synthesis and DNA binding by NF-
κB and STAT-3 transcription factors. Furthermore, 
experiments with IL-6-deficient animals demonstrate 
that IL-6 is a critical component of the regenerative 
response: after PH, IL-6-/- mice had impaired liver 
regeneration characterized by liver necrosis and 
failure (23), and a significantly impaired activation of 
STAT3 and NF-κB.  
 
The production of IL-6 and TNF-α is 
mediated, at least in part, by the innate immune 
system. Release of IL-6 from Kupffer cells can be 
triggered by C5a (a complement component) in 
concert with LPS, thereby mediating the expression 
of acute-phase genes in cultured hepatocytes (24). 
Moreover, C3a is can modulate prostaglandin 
synthesis (25) and alter production of IL-6, TNF-α, 
and IL-1β (26-28). Results from C3 or C5 knockout 
mice demonstrate the essential role of complement in 
liver regeneration. After PH, these mice show a 
diminished liver regeneration accompanied by 
transient or fatal liver failure; and in mice with dual 
C3 and C5 deficiency the phenotype is more 
exacerbated (29,30). Additionally, inhibition of C5a 
receptor signaling suppresses IL-6/TNF-α induction; 
and lack of C3 and C5a receptor stimulation 
attenuates NF-κB/STAT3 activation after 
hepatectomy.  
 
 3.1.2. Growth-factor-pathways activated during 
liver regeneration.  
In addition to cytokines, growth factors 
regulate liver regeneration by providing both 
stimulatory and inhibitory signals for cell 
proliferation. Among the extracellular growth factors 
shown to induce hepatocyte proliferation, hepatocyte 
growth factor (HGF/SF), transforming growth factor 
α (TGF-α), and epidermal growth factor (EGF), as 
well as their receptors, have been particularly well 
studied. These growth factors stimulate DNA 
synthesis in hepatocytes, and are strong candidates for 
important roles in liver regeneration (31,32).  
 
HGF is a potent mitogen for a variety of 
cells, including hepatocytes. HGF is synthesized by 
non-parenchymal cells, particularly stellate cells, and 
activates the receptor tyrosine kinase Met and various 
downstream pathways, including those that involve 
PI3K, ERK, S6 kinase and AKT (33,34).  Gene 
knockout of HGF (35,36) or its receptor, Met, is 
embryonic lethal (31):(32) these animals die in utero 
between embryonic days 13.5 and 16.5 with multiple 
abnormalities, including signs of underdeveloped 
liver. Therefore, in order to determine the 
contribution of these factors to liver regeneration, 
studies have been conducted ina liver-specific 
conditional knockout of Met. The results of these 
studies demonstrate that the HGF–Met pathway is 
important for DNA synthesis after liver injury (31). 
 
The initiation of liver regeneration by HGF 
first requires the activation of HGF from its 
precursor, pro-HGF, by proteases such as uPA 
(urokinase-type plasminogen activator) (37,38). In 
mice deficient in uPA the appearance of HGF is 
delayed, which in turn delays liver regeneration (39). 
However, liver regeneration is unaffected in mice 
deficient in the uPA receptor (uPAR), indicating that 
whatever role uPA may play in liver regeneration it 
does not require binding to uPAR. 
 
In the regenerating liver, TGF-α is 
expressed in hepatocytes a few hours after the HGF 
surge in the circulation, but before the start of DNA 
synthesis. In spite of the strong correlative evidence 
linking TGF-α expression and hepatocyte 
proliferation, TGF-α knockout mice grow normally 
and have no deficit in liver regeneration (36). TGF-α 
is a member of the epidermal growth factor family, 
and shares homology with EGF. These growth factors 
shares a common receptor, the EGF receptor (EGFR) 
(40); and it is possible that liver regeneration requires 
activation of the EGFR per se, but that the specific 
identity of the ligand is unimportant. However, mice 
with a null mutation in the EGFR(41) die either at the 
blastocyst stage or in utero from placental failure, and 
so cannot provide information on the requirement for 
EGFR signaling in liver regeneration. Recent results 
have demonstrated that HB-EGF (heparin-binding 
epidermal growth factor-like growth factor) may be 
an important factor in PH. HB-EGF is produced 
earlier after PH than HGF, and acts by a paracrine 
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mechanism (42).  HB-EGF knockout mice manifest a 
delay in DNA replication after PH (43). 
 
3.1.3. Transcription factors. 
The activation of growth factor and 
cytokine signaling pathways after PH induces the 
activities of several transcription factor complexes. 
These include NF-κB and STAT3 (which are both 
strongly induced by TNF-α), AP-1, c-Myc, CREM 
and C/EBPβ (CCAAT/enhancer-binding proteins). 
These transcription factors play major roles in the 
initiation of liver regeneration (11,18,19).  
 
NF-κB activation is particularly rapid, 
occurring within 30 minutes after PH. NF-κB 
activates multiple target genes that have an NF-κB 
recognition sequence, such as the gene for IL-6, 
which itself causes activation of STAT3. Blockage of 
NF-κB activity, by infecting livers of rats with an 
adenovirus expressing a truncated form of IκB (44), 
has a major apoptotic effect in the regenerating liver.  
 
STAT3 is ubiquitously expressed and 
transiently activated by a variety of different ligands, 
including IL-6, leukemia-inhibitory factor (LIF), 
EGF, and platelet-derived growth factor (PDGF), as 
well as by a number of oncogenic receptor and non-
receptor tyrosine kinases (45-49). STAT3 plays a 
crucial role in the embryonic development of various 
organs and in cell proliferation (49). Knockout of 
Stat3 is embryonic lethal, so experiments have been 
conducted with liver-specific Stat3 knockouts. These 
experiments demonstrate that STAT3 promotes cell-
cycle progression and cell proliferation under 
physiological growth conditions. 
 
The expressions and activities of several 
C/EBP isoforms fluctuate in the regenerating liver. 
Among them, increased expression of C/EBPβ after 
PH seems to indicate an important role in liver 
regeneration. Indeed, Greenbaum et al. have 
presented evidence showing that C/EBPβ knockout 
mice exhibit impaired hepatocyte proliferation and 
decreased liver regeneration after PH (50). 
 
The DNA binding activity of AP-1 is 
rapidly induced in response to PH (51). AP-1 is a 
heterodimeric sequence-specific transcription factor 
most commonly composed of the products of the jun 
and fos families of genes. AP-1 activity is increased 
both by growth factor and by cytokine signaling 
pathways, although through different mechanisms. A 
TNF-α/IL-6-dependent signal stimulates c-Fos (6), 
and c-Jun is stimulated by a second mechanism, 
possibly emanating from growth factor receptors. 
JNK activity increases after PH; and, in contrast to c-
fos (knockout animals deficient in this gene have a 
normal regenerative response), c-jun is likely to be 
important for hepatocyte proliferation. However, 
study of c-Jun’s role is not possible in standard 
knockout models: fetuses lacking c-jun die at mid-
gestation with defects in heart morphogenesis and 
increased apoptosis of both hepatoblasts and 
hematopoietic cells in the fetal liver (52).  To bypass 
this embryonic lethality, conditional mice have been 
developed to suppress c-jun expression in adult mice 
(53). These experiments show that c-Jun is a critical 
regulator of hepatocyte proliferation and survival 
after liver injury.  
 
4. ROLE OF NOS-2 AND COX-2 IN LIVER 
REGENERATION  
 
The rapid activation of transcription factors 
induces the expression of key enzymes that control 
the regenerative process downstream of this point. 
Among these enzymes are NOS-2 (6,18,54), which 
catalyses the formation of NO, and cyclooxygenase-2 
(COX-2), which catalyzes the rate-limiting step in the 
synthesis of prostaglandins (PGs). Both proteins are 
expressed after PH in the remnant tissue, and serum 
levels of PGE2 increase. PGs produced by COX-2 are 
important for the early steps of liver regeneration, 
participating in the regulation of the cell cycle after 
PH. 
 
4.1. Regulation of liver regeneration by NO. 
NOS-2 is expressed after PH by 
hepatocytes and by Kupffer cells, and the NO 
released plays a regulatory role in liver regeneration 
(54,55). Indeed, inhibition of NOS-2 delays early 
cell-cycle progression after PH (54).  NO release 
seems to be a local effect, because hepatic NOS 
activity and levels of NOS mRNA have been detected 
exclusively in liver. Although the relative 
contributions of each liver cell type to NO synthesis 
differ (Kupffer cells produce more NO than 
hepatocytes), the origin of NO is not critical, since it 
can diffuse through the cells. NOS-2 levels are 
mainly controlled at the transcriptional level; and 
activation of NF-κB has been reported to be essential 
for NOS-2 transcription (56).  
 
Several animal models have been used to 
study the role of NO in liver regeneration. 
Experiments in NOS-2 knockout mice demonstrated 
that hepatocytes undergo apoptosis and necrosis 
instead of proliferation when the expression of NOS-
2 is prevented in the regenerating liver (57). The PH-
induced NOS-2 expression occurs preferentially in 
hepatocytes (54,55); and the NO released protects 
regenerating liver cells from the pro-apoptotic effects 
of increased TNF-α concentration and endotoxemia 
(57-59) by S-nitrosylating procaspases and active 
caspase enzymes (60). 
 
Two innovative genetic strategies have 
been used recently to study the protective role of NO 
during liver regeneration. Both strategies allow 
controlled delivery of NO to liver. In the first 
approach animals express a NOS-2 transgene under 
the control of the liver-specific phospho(enol) 
pyruvate carboxykinase promoter (PEPCKNOS2 
animals). The expression of this gene, and therefore 
NO release, is triggered under fasting conditions. The 
second approach involves the hydrodynamics-based 
in vivo transfection of animals with a plasmid 
encoding NOS-2 (61). 
 
 
4.1.1. PEPCKNOS2 animals 
Endogenous production of NO in 
hepatocytes by expression of an NOS-2 transgene 
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under the control of the PEPCK promoter (58) is one 
of the most interesting models for the study of liver 
regeneration. This model has several advantages. 
First, NO is specifically and endogenously generated 
in liver, thus avoiding the many undesirable side 
effects due to the as yet unresolved difficulty of 
selective delivery of exogenous NO to the organ. 
Second, NO synthesis is triggered by a simple 
process that is independent of proinflammatory 
stimulation. Finally, because the PEPCK promoter is 
activated in the postnatal period, interference in the 
course of animal development is avoided.  
With this approach, the expression of NOS-
2 in transgenic (Tg) animals, which is undetectable in 
fed animals, is observed after starvation for 24 h 
(figure 2). This expression in fasted animals promotes 
a moderate change in parameters related to oxidative 
stress, but does not significantly affect life-span, an 
nor does it involve other systemic alterations of the 
normal behavior of the Tg animals with respect to the 
corresponding wild-types. Apart from minor 
expression in kidney, NOS-2 is not expressed in other 
organs of PEPCKNOS-2 Tg mice. These data suggest 
that moderate generation of NO in the liver has no 
noticeably deleterious effects on the organ.  
 
Study of fasted PEPCKNOS-2 Tg animals 
shows that preexistent synthesis of NO in the 
hepatocyte protects against lipopolysaccharide (LPS)-
induced liver injury (58). The mechanisms that 
mediate this protection seem to include the inhibition 
of NF-κB activation and the impairment of the 
release of TNF-α, IL-1β, and presumably of other 
proinflammatory cytokines whose expression is 
dependent on NF-κB activity (62). However, 
preexistent synthesis of NO, derived from expression 
of the PEPCKNOS-2 transgene impairs the later 
expression of NOS-2 from the endogenous gene after 
PH. This delays subsequent early signaling and liver 
mass recovery, although there is no effect on mouse 
survival (63). The mechanism underlying this delay 
in liver mass recovery in Tg mice involves 
impairment of the degradation of IκB-α and a 
consequently lowered NF-κB activation. STAT3 
phosphorylation and the amounts of cytokines (TNF-
α and IL-6) are also significantly reduced in these 
animals .The local presence of NO before PH also 
delays hepatocyte proliferation through an inhibition 
of the cell cycle proteins cyclin E, cyclin D1, and 
PCNA.  
 
In spite of its antiproliferative and 
cytostatic effects, NO efficiently protected 
hepatocytes from apoptosis in Tg animals. These 
hepatoprotective and antiapoptotic effects of NO 
have been previously described in several 
pathological situations such as carbon tetrachloride-
induced hepatic injury (64) or Fas-dependent 
apoptosis, which plays a major role in the 
pathogenesis of immuno-mediated liver diseases such 
as viral hepatitis and acute liver failure (65-67). 
 
4.1.2. Hydrodynamics-based transfection in mice 
The second approach to liver-targeted NO 
delivery consists of an in vivo transfection of NOS-2 
directly to the liver by the hydrodynamics-plasmid 
delivery procedure (61). By using GFP-NOS-2 cDNA 
as a reporter gene, an efficient gene transfer and 
expression can be achieved by a rapid injection of a 
large volume of DNA solution into animals via the 
tail vein. The procedure results in a marked 
expression of the transfected gene in various major 
organs including the liver, kidney, lung, heart and 
spleen. Among these, the highest expression is in the 
liver, with approximately 40 percent of hepatocytes 
expressing the transfected gene.  The reason for this 
is the accumulation of the injected DNA solution in 
the inferior vena cava, which produces a high 
hydrostatic pressure that forces the flow of a large 
portion of DNA solution into the liver in a retrograde 
direction. The time-response curve shows that the 
level of transfected gene expression in the liver peaks 
approximately 8 h after injection and decreases 
thereafter. Peak gene expression can be regained by 
repeated injection of plasmid DNA. The 
hydrodynamics-based procedure causes no serious 
liver damage: a transient increase in serum 
transaminases has been detected, but the levels of 
these enzymes return to normal values within few 
days (61). 
 
The hydrodynamics-based transfection 
model has been used to determine the role of 
sustained presence of NO before and during PH. The 
NOS-2 transfected animals show a response similar 
to that observed in the PEPCK-NOS-2 Tg mice, with 
a pattern of delayed cell cycle protein expression with 
respect to controls. Moreover, a significant protection 
against Fas-dependent apoptosis (detected as reduced 
activation of caspases) is triggered by the transient 
expression of NOS-2. 
 
The two experimental models outlined 
above highlight the importance of correct regulation 
of NOS-2 expression in the regenerating liver. 
Although the role of NO in liver regeneration is 
essentially protective – favoring hepatic circulation 
and contributing to the angiogenic activity in the 
remnant tissue – the presence of NO before liver 
injury prevents the normal expression of the 
endogenous NOS-2 gene after injury, thus inhibiting 
liver mass recovery. To be effective, NOS-2 
expression must be timed to release NO at the 
appropriate moment (figure 3). 
 
  
 
4.2. Involvement of prostaglandins in liver 
regeneration 
Liver regeneration is also characterized by 
an altered pattern of the expression of prostaglandins 
(PGs). Indeed, an accumulation of PGE2 has been 
described in the sera of animals after PH. PGs are 
synthesized by the cyclooxygenase isoenzymes, 
COX-1 and COX-2. COX-2, the inducible isoform, 
may contribute to liver damage and tumorigenesis in 
several animal models.  Expression of COX-2 has 
been demonstrated in liver regeneration after PH, 
with a maximal expression after 16 h (2). The 
expression of COX-2 in regenerating liver is 
accompanied by a decrease in the level of C/EBP-α 
and an increase in the expression of C/EBP-β and 
C/EBP-δ. Inhibition of COX-2 activity, either 
pharmacologically with NS398 or by gene knockout, 
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impairs liver regeneration (68) and alters various 
parameters of cell-cycle progression (PCNA levels, 
cyclins E and D1) (69).  
 
4.3. Lethal failure of liver regeneration after 
simultaneous abrogation of NOS-2 and COX-2. 
Given the importance of NO and PGs 
during liver regeneration, the simultaneous 
suppression of NOS-2 and COX-2 activities is 
potentially lethal. COX-2 knockout has severe 
systemic defects, and animals die early. A double 
knockout approach is therefore unsuitable for the 
analysis of the combined contribution of COX-2 and 
NOS-2 to liver regeneration. In place of this, a 
pharmacological approach using COX-2 inhibitors 
has been used in NOS-2 knockout animals. 
Simultaneous suppression of the activities of NOS-2 
(by gene knockout) and COX-2 (by pharmacological 
inhibition) results in an imbalance between 
regenerating cells and cells undergoing apoptosis 
(70). This results in massive hepatocyte death, which 
can be prevented by the exogenous supply of NO or 
the administration of the broad caspase inhibitor z-
VAD, allowing animals to regenerate the liver (figure 
4). 
 
5. SUMMARY AND PERSPECTIVE. 
 
The experimental findings reviewed here 
clearly show that NO and PGs have a profound effect 
on the liver's ability to regenerate after it has been 
damaged, and suggest that regeneration requires the 
induction of factors that protect proliferating cells 
from death. Principal among these is NO; therefore 
the development of strategies for local delivery of 
NO to the liver is an area of great interest for the 
therapeutic treatment of several hepatopathies. 
 
However, neither NO nor PGs are essential, 
at least independently, for liver regeneration after PH: 
other factors can compensate for NOS-2 or COX-2 
deficiency. These findings illustrate that the signaling 
pathways involved in liver regeneration are 
coordinated and redundant, so that, in general, more 
than one signal must be inactivated for the effect to 
be lethal. 
 
The increased use of transgenic and 
knockout mice has undoubtedly contributed major 
advances to the understanding of the mechanisms of 
liver regeneration. Gene manipulation in mice with 
new technologies that allow conditional and tissue-
specific expression of genes will continue to advance 
knowledge of the mechanisms that regulate and 
promote regeneration. However, given the 
redundancy of signaling pathways involved in liver 
regeneration, strategies directed at simultaneous 
deletion of two or more genes must be considered.  
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Figure 1. Signaling pathways activated during 
liver regeneration. After PH or liver injury, several 
signals are initiated simultaneously in the liver. 
Cytokine-regulated and growth-factor-pathways are 
activated, leading to the binding of VEGF to 
endothelial cells, which triggers the release of HGF 
from stellate cells, and to the activation of Kupffer 
cells that release cytokines such as TNF-α, ΙL-1β and 
IL-6. Cooperative signals from these stimuli activate 
transcription factors (NF-κB and STAT3) and, in 
turn, the expression of genes whose transcription is 
κB-dependent, such as NOS-2 and COX-2. For a 
more detailed revision of early signaling involved in 
liver regeneration see reference 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effects of sustained NO synthesis on 
liver regeneration. (A) 6.2-kb fragment containing 
the NOS-2 gene under the transcriptional control of 
the PEPCK promoter (PEPCKNOS-2). (B) Western 
blot of liver extracts showing the expression of NOS-
2 in PEPCKNOS-2 transgenic (Tg) animals fasted for 
24 h. (C) EMSA showing activation of NF-κB after 
liver injury (by administration of LPS/D-GalN or 
resection by PH) in wild-type (WT) and Tg mice. (D) 
Liver injury caused by these treatments, detected as 
serum levels of alanine aminotransferase (ALT). 
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Figure 3. Dual action of NO after liver injury. 
Sustained NOS-2 expression in liver can be achieved 
by two experimental delivery methods: the PEPCK-
NOS-2 model; and the hydrodynamic transfection 
procedure. The presence of NO before and after liver 
injury (LPS/D-GalN or PH) exerts different effects 
via a common mechanism. NO inhibits activation of 
NF-κB, cytokine release, and apoptosis, leading to 
the protection against LPS/D-GalN injury; however, 
preexisting NO delays liver mass recovery after PH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Simultaneous abrogation of NOS-2 and 
COX-2 activities is lethal after PH. After PH 
several signaling pathways are activated. Important 
among these events are increased expression of NOS-
2 and COX-2, which release NO and PGs, 
respectively. When these enzymes are simultaneously 
inhibited through pharmacological inhibition of 
COX-2 activity with DFU and gene knockout (KO) 
of NOS-2, liver mass recovery is prevented, resulting 
in death.    
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